Sona Nanotech Inc
CNSX:SONA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Country Average (20.4), the stock would be worth CA$-0.37 (219% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -17.2 | CA$0.31 |
0%
|
| Country Average | 20.4 | CA$-0.37 |
-219%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
S
|
Sona Nanotech Inc
CNSX:SONA
|
35.5m CAD | -17.2 | -11.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 1 841 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 31.4 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 26.2 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 105.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
329.9B CNY | 25.4 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | -164.7 | -119.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 34.3 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 55.3 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 18.9 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 32.7 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 20.4 |
| 70th Percentile | 33.5 |
| Max | 22 577.3 |
Other Multiples
Sona Nanotech Inc
Glance View
Sona Nanotech, Inc. is a nanotechnology life sciences company, which engages in the development and manufacture of rod-shaped gold nanoparticles. The company is headquartered in Halifax, Nova Scotia and currently employs 8 full-time employees. The company went IPO on 2018-10-04. The firm is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The firm's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
